Compare Sana Biotechnology Inc (SANA) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs TKO Group Holdings Inc — how do they compare? Sana Biotechnology Inc trades at $3.79 (market cap $1.13B), while TKO Group Holdings Inc trades at $195.16 (market cap $14.24B). The key difference: TKO Group Holdings Inc is far larger — about 12.6× Sana Biotechnology Inc's market cap, and TKO Group Holdings Inc pays a 1.6% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | TKO | |
|---|---|---|
Market Cap | $1.13B | $14.24B |
Sector | Health | Technology |
52-Week High | $5.92 | $224.96 |
52-Week Low | $2.68 | $176.49 |
Enterprise Value | $1.05B | $18.60B |
Dividend Yield | — | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
TKO trades at $195.14, up 3.02% today, with a bullish technical outlook supported by moving averages and strong institutional sentiment. Recent Q2 2026 results showed revenue of $1.55 billion, an 18% YoY increase, though EPS of $1.34 missed expectations. The company raised full-year guidance, reflecting confidence in media rights and live events. Analyst consensus is strongly bullish with an average price target of $228.17, representing 17% upside from current levels.
TKO's growth trajectory is supported by expanding media deals and global events, but high valuation multiples (P/E 68.33) pose risks if execution falters. Key opportunities include continued revenue momentum from UFC and WWE, while risks involve earnings volatility and competitive pressures. The stock remains attractive for growth-oriented investors despite premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
